Andexanet

BIOLOGICAL3 trials

Sponsors

Portola Pharmaceuticals, Alexion Pharmaceuticals, Inc.

Conditions

Bleeding

Phase 3

A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban

CompletedNCT02207725

Portola PharmaceuticalsBleeding

Start: 2014-03-31End: 2015-09-30Updated: 2023-08-08

A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban

CompletedNCT02220725

Portola PharmaceuticalsBleeding

Start: 2014-05-31End: 2015-08-31Updated: 2023-02-10

A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)

CompletedNCT02329327

Alexion Pharmaceuticals, Inc.Bleeding

Start: 2015-04-10End: 2020-09-24Updated: 2022-02-16

Related Papers

Andexanet alfa versus non-specific treatments for intracerebral hemorrhage in patients taking factor Xa inhibitors — Individual patient data analysis of ANNEXA-4 and TICH-NOAC

International Journal of Stroke2024-01-2417 citations

Predictors of Intracranial Hemorrhage Volume Expansion in Patients Receiving Factor Xa Inhibitors in ANNEXA‐4: Time and Severity Matter Most

Stroke Vascular and Interventional Neurology2023-12-206 citations

Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors

Circulation2023-02-20129 citations

Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis

Critical Care2022-06-1664 citations

Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor–Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care

Stroke2021-10-1461 citations

Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy

Stroke2021-05-1062 citations

Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors

New England Journal of Medicine2019-02-07920 citations

Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors

New England Journal of Medicine2016-08-30773 citations

Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity

New England Journal of Medicine2015-11-111028 citations